Predictive value of antibodies to citrullinated peptides and rheumatoid factors in anti-TNF-α treated patients

Annals of the New York Academy of Sciences

Volumn 1109, Issue , 2007, Pages 287-295

  Bobbio Pallavicini, Francesca ^a   Caporali, Roberto ^a   Alpini, Claudia ^a   Moratti, Remigio ^a   Montecucco, Carlomaurizio ^a,b  

^a UNIVERSITY OF PAVIA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Anti cyclic citrullinated peptide antibodies; Rheumatoid arthritis; Rheumatoid factor; Tumor necrosis factor inhibitors

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLD SALT; INFLIXIMAB; METHOTREXATE; RHEUMATOID FACTOR; RITUXIMAB; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; AUTOANTIBODY; PEPTIDE;

CLINICAL TRIAL; CONFERENCE PAPER; HUMAN; RADIOFREQUENCY; RHEUMATOID ARTHRITIS; SEROLOGY; SERUM; TREATMENT RESPONSE; ARTICLE; BLOOD; IMMUNOLOGY; PATHOLOGY;

ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; HUMANS; PEPTIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34848842839     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1398.034     Document Type: Conference Paper

References (51)

1. VANDER CRUYSSEN, B., I. PEENE, T. CANTAERT, et al. 2005. Anti-citrullinated protein/peptide antibodies (ACPA) in rheumatoid arthritis: specificity and relation with rheumatoid factor. Autoimmun. Rev. 4: 468-474.
2. FORSLIND, K., M. AHLMEN, K. EBERHARDT, et al. 2004. Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann. Rheum. Dis. 63: 1090-1095.
3. KASTBOM, A., G. STRANDBERG, A. LINDROOS, et al. 2004. Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann. Rheum. Dis. 63: 1085-1089.
4. RONNELID, J., M.C. WICK, J. LAMPA, et al. 2005. Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression. Ann. Rheum. Dis. 64: 1744-1749.
5. KROOT, E.J., B.A. DE JONG, M.A. VAN LEEUWEN, et al. 2000. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum. 43: 1831-1835.
6. VENCOVSKY, J., S. MACHACEK, L. SEDOVA, et al. 2003. Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Ann. Rheum. Dis. 62: 427-430.
7. RAZA, K., M. BREESE, P. NIGHTINGALE, et al. 2005. Predictive value of antibodies to cyclic citrullinated peptide in patients with very early inflammatory arthritis. J. Rheumatol. 32: 231-238.
8. JOHNSON, P.M. & W.P. FAULK. 1976. Rheumatoid factor: its nature, specificity, and production in rheumatoid arthritis. Clin. Immunol. Immunopathol. 6: 414-430.
9. BAS, S., T.V. PERNEGER, E. KUNZLE, et al. 2002. Comparative study of different enzyme immunoassays for measurement of IgM and IgA rheumatoid factors. Ann. Rheum. Dis. 61: 505-510.
10. SWEDLER, W., J. WALLMAN, C.J. FROELICH, et al. 1997. Routine measurement of IgM, IgG, and IgA rheumatoid factors: high sensitivity, specificity, and predictive value for rheumatoid arthritis. J. Rheumatol. 24: 1037-1044.
11. ZLABINGER, G.J., G. HABERHAUER, K. DAX, et al. 1990. Rheumatoid factor isotypes and circulating immune complexes in rheumatoid arthritis. Clin. Exp. Rheumatol. 8: 113-119.
12. JORGENSEN, C., M.C. LEGOUFFE, C. BOLOGNA, et al. 1996. IgA isotype rheumatoid factor in rheumatoid arthritis: clinical implications. Clin. Exp. Rheumatol. 14: 301-304.
13. BERGLIN, E., T. JOHANSSON, U. SUNDIN, et al. 2006. Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset. Ann. Rheum. Dis. 65: 453-458.
14. OLSEN, N.J., G.P. TEAL & R.H. BROOKS. 1991. IgM- rheumatoid factor and responses to second-line drugs in rheumatoid arthritis. Agents Actions. 34: 169-171.
15. ALARCON, G.S., R.E. SCHROHENLOHER, A.A. BARTOLUCCI, et al. 1990. Suppression of rheumatoid factor production by methotrexate in patients with rheumatoid arthritis. Evidence for differential influences of therapy and clinical status on IgM and IgA rheumatoid factor expression. Arthritis Rheum. 33: 1156-1161.
16. OLSEN, N.J., L.F. CALLAHAN & T. PINCUS.1988. In vitro rheumatoid factor synthesis in patients taking second-line drugs for rheumatoid arthritis. Independent associations with disease activity. Arthritis Rheum. 31: 1090-1096.
17. POPE, R.M., J. LESSARD & E. NUMMERY. 1986. Differential effects of therapeutic regimens on specific classes of rheumatoid factor. Ann. Rheum. Dis. 45: 183-189.
18. HANLY, J.G., J. HASSAN, A. WHELAN, et al. 1986. Effects of gold therapy on the synthesis and quality of serum and synovial fluid IgM, IgG and IgA rheumatoid factors in rheumatoid arthritis patients. Arthritis Rheum. 29: 480-487.
19. KLOPPENBURG, M., B.A. DIJKMANS, C.L. VERWEIJ, et al. 1996. Inflammatory and immunological parameters of disease activity in rheumatoid arthritis patients treated with minocycline. Immunopharmacology 31: 163-169.
20. KANERUD, L., G.N. ENGSTROM & A. TARKOWSKY. 1995. Evidence for differential effects of sulphasalazine on systemic and mucosal immunity in rheumatoid arthritis. Ann. Rheum. Dis. 54: 256-262.
21. SCOTT, D.L., P.T. DAWES, M. COLLINS, et al. 1987. ELISA assays for IgM and IgG rheumatoid factors: their clinical correlations during therapy with slow-acting anti rheumatic drugs. Clin. Rheumatol. 6: 358-368.
22. SPADARO, A., V. RICCIERI, A. SILI SCAVALLI, et al. 1993. One year treatment with lowdose methotrexate in rheumatoid arthritis: effect on class specific rheumatoid factors. Clin. Rheumatol. 12: 357-360.
23. MIKULS, T.R., J.R. O'DELL, J.A. STONER, et al. 2004. Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody. Arthritis Rheum. 50: 3776-3782.
24. WERNICK, R., P. MERRYMAN, I. JAFFE, et al. 1983. IgG and IgM rheumatoid factors in rheumatoid arthritis. Quantitative response to penicillamine therapy and relationship to disease activity. Arthritis Rheum. 26: 593-598.
25. BOBBIO-PALLAVICINI, F., C. ALPINI, R. CAPORALI, et al. 2004. Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. Arthritis Res. Ther. 6: R264-R272.
26. DE RYCKE, L., X. VERHELST, E. KRUITHOF, et al. 2005. Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis. Ann. Rheum. Dis. 64: 299-302.
27. ATZENI, F., P. SARZI-PUTTINI, D. DELL' ACQUA, et al. 2005. Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study. Arthritis Res. Ther. 8: R3.
28. ALESSANDRI, C., M. BOMBARDIERI, N. PAPA, et al. 2004. Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFα therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann. Rheum. Dis. 63: 1218-1221.
29. YAZDANI-BIUKI, B., E. STADLMAIER, A. MULABECIROVIC, et al. 2005. Blockade of tumour necrosis factor {alpha} significantly alters the serum level of IgG- and IgA-rheumatoid factor in patients with rheumatoid arthritis. Ann. Rheum. Dis. 64: 1224-1226.
30. CHARLES, P.J., R.J. SMEENK, J. DE JONG, et al. 2000. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumour necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum. 43: 2383-2390.
31. CARAMASCHI, P., D. BIASI, E. TONOLLI, et al. 2005. Antibodies against cyclic citrullinated peptides in patients affected by rheumatoid arthritis before and after infliximab treatment. Rheumatol. Int. 26: 58-62.
32. ALLANORE, Y., J. SELLAM, F. BATTEUX, et al. 2004. Induction of autoantibodies in refractory rheumatoid arthritis treated by infliximab. Clin. Exp. Rheumatol. 22: 756-758.
33. CHEN, H.A., K.C. LIN, C.H. CHEN, et al. 2006. The effect of etanercept on anticyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis. Ann. Rheum. Dis. 65: 35-39.
34. NISSINEN, R., M. LEIRISALO-REPO, R. PELTOMAA, et al. 2004. Cytokine and chemokine receptor profile of peripheral blood mononuclear cells during treatment with infliximab in patients with active rheumatoid arthritis. Ann. Rheum. Dis. 63: 681-687.
35. BENUCCI, M., S. TURCHINI, P. PARROCHI P, et al. 2006. Correlation between different clinical activity and anti-CCP (anti-cyclic citrullinated peptide antibodies) titres in rheumatoid arthritis treated with three different tumour necrosis factors TNF-α blockers. Recenti Prog. Med. 97: 134-139.
36. BOBBIO PALLAVICINI, F., R. CAPORALI, C. ALPINI, et al. 2007. High IgA rheumatoid factor levels are associated with poor clinical response to tumor necrosis alpha inhibitors in rheumatoid arthritis. Ann. Rheum. Dis. 66(3): 302-307.
37. CAVAZZANA, I., F. BOBBIO-PALLAVICINI, C. BAZZANI, et al. 2006. TNFα inhibition in anti-Ro/SSa positive patients with rheumatoid arthritis: clinical and immunological effects. Reumatismo 58: 275- 282.
38. ERIKSSON, C., S. ENGSTRAND, K.G. SUNDQVIST, et al. 2004. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF-α therapy. Ann. Rheum. Dis. 64: 403-407.
39. LOUIS, M., J. RAUCH, M. ARMSTRONG, et al. 2003. Induction of autoantibodies during prolonged treatment with Infliximab. J. Rheum. 30: 2557-2562.
40. JONSDOTTIR, T., J. FORSLID, A. VAN VOLLENHOVEN, et al. 2004. Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies. Ann. Rheum. Dis. 63: 1075-1078.
41. WEINBLATT, M.E., E.C. KEYSTONE, D.E. FURST, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 48: 35-45.
42. CUSH, J.J. 2004. Unusual toxicities with TNF inhibition: heart failure and drug-induced lupus. Clin. Exp. rheumatol. 22(Suppl):S141-147.
43. FERRARO-PEYRET, C., F. COURY, J.G. TEBIB, et al. 2004. Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphosphpolipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study. Arthritis Res. Ther. 6: R535-R543.
44. ATZENI, F., P. SARZI PUTTINI, D. DELL'ACQUA, et al. 2006. Anticorpi antinucleo e trattamento con 3 differenti agenti anti-tumour necrosis factor-α [abstract]. Reumatismo 58: 348.
45. HYRICH, K.L., A.J. SILMAN, K.D. WATSON, et al. Anti-TNF(alpha) therapy in rheumatoid arthritis: an update on safety. Ann. Rheum. Dis. 63: 1538-1543.
46. VAN GESTEL, A.M., M.L. PREVOO, M.A. VAN'T HOF, et al. 1996. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Arthritis Rheum. 39: 34-40.
47. EDWARDS, J.C.W., L. SZCZEPANSKI, J. SZECHINSKI, et al. 2004. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 350: 2572-2581.
48. CAMBRIDGE, G., W. STOHL, M.J. LEANDRO, et al. 2006. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum. 54: 723-732.
49. HYRICH, K.L., K.D. WATSON, A.J. SILMAN, et al. 2006. Predictors of response to anti-TNF-α therapy amang patients with rheumatoid arthritis: results from British Society for Rheumatology Biologics Register. Rheumatology 45: 1558-1565.
50. EMERY, P., R. FLEISHMANN, A. FILIPOWICZ-SOSNOWSKA, et al. 2006. The efficacy and safety of rituximab in patients with active arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 54: 1390-1400.
51. O'DELL, J.R. 2002. Treating rheumatoid arthritis early: a window of opportunity? Arthritis Rheum. 46: 283- 285.